Clinical Trials: Page

  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Corvus shares nearly triple on positive data for eczema pill

    While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

    By • Jan. 21, 2026
  • Person standing up and speaking to a board room full of people.
    Image attribution tooltip
    Permission granted by Almac Clinical Services
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    When every day counts: Building CRO partnerships on a foundation of trust, care and precision

    Clinical trial delays impact outcomes. Learn why CROs need a supply chain partner they can trust to reduce delays and help patients. 

    Jan. 20, 2026
  • Radiopharmaceutical Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Radiopharmaceuticals

    A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

    By BioPharma Dive staff
  • A woman sits on a sofa, holding a smartphone, appearing thoughtful. She's surrounded by plants, with a relaxed, cozy atmosphere in warm lighting.
    Image attribution tooltip

     

    1nHealth

    Image attribution tooltip
    Sponsored by 1nHealth

    The patient retention crisis is happening before enrollment even begins

    The biggest patient drop-off happens before patients ever enroll.

    By Katie Rodammer • Jan. 20, 2026
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tecvayli tops standard drugs in early multiple myeloma, J&J says

    The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher. 

    By • Jan. 15, 2026
  • Sanofi
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    What Sanofi’s multiple sclerosis troubles could mean for the space

    Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many opportunities to make an impact.

    By Kelly Bilodeau • Jan. 13, 2026
  • medical scientists analyzing research scans on a computer,
    Image attribution tooltip
    Sean Anthony Eddy via Getty Images
    Image attribution tooltip
    Sponsored by Pearson

    Best practices for COA selection: Building a stronger foundation for clinical trials

    In a time when COAs are more nuanced, critical and complex than ever, researchers can turn to best practices to move forward efficiently while maintaining scientific and regulatory rigor.

    Jan. 12, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK, Ionis claim study success for RNA-based hepatitis B drug

    The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

    By Kristin Jensen • Jan. 7, 2026
  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Alumis soars as TYK2 drug hits mark in psoriasis trials

    Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.

    By • Jan. 6, 2026
  • Wall street sign in New York City with New York Stock Exchange background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Zenas shares crash after top drug misses expectations in immune disease study

    While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

    By • Jan. 5, 2026
  • Doctors checking charts on computer screen
    Image attribution tooltip
    Permission granted by LifeLabs
    Image attribution tooltip
    Sponsored by LifeLabs

    Strategic diagnostic testing partnerships are accelerating clinical research

    With the rise of biologics, precision medicine and AI-driven drug discovery, clinical research has entered a new and complex era.

    Jan. 5, 2026
  • An all-green glass building facade with a logo that reads "MERCK" is displayed on the exterior of the research facility.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Patient deaths put Merck, Daiichi’s ADC trial on partial hold

    The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” in people with small cell lung cancer.

    By • Dec. 19, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo files for CagriSema approval; Merck and Pfizer’s trial win

    Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

    By BioPharma Dive staff • Dec. 19, 2025
  • The entrance to Galapagos' corporate offices are lit up at dusk.
    Image attribution tooltip
    Courtesy of Galapagos
    Image attribution tooltip

    Galapagos TYK2 drug hits goal in one trial, misses in another

    The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin and muscle disorder but missed in a lupus study.

    By • Dec. 19, 2025
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

    Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could broaden its use in obesity. 

    By • Dec. 18, 2025
  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Insmed’s ‘win streak’ ends as top drug fails study in chronic nasal condition

    The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely followed lung disease medicine.

    By Kristin Jensen • Dec. 18, 2025
  • A photo of Takeda president of R&D Andy Plump.
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    Takeda says $4B TYK2 drug succeeds in large psoriasis studies

    The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.

    By • Dec. 18, 2025
  • Research worker in a lab
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip
    Sponsored by Pfizer

    Developing a path forward in cancer cachexia

    Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.

    Dec. 16, 2025
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study

    Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving into late-stage testing. 

    By Kristin Jensen • Dec. 16, 2025
  • Close-up on a scientist using a mobile app on a digital tablet while working at the laboratory
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx falters in effort to expand immune drug’s use

    The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to be ineffective at an interim checkpoint.

    By • Dec. 15, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi MS drug hits two setbacks

    Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the disease.

    By • Dec. 15, 2025
  • A photo of Kyverna Therapeutics the day of its initial public offering on the Nasdaq stock exchange.
    Image attribution tooltip
    Permission granted by Kyverna Therapeutics
    Image attribution tooltip
    Immune reset

    Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease

    The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition called stiff person syndrome that has no approved therapies. 

    By • Dec. 15, 2025
  • Computer, reading and doctor asian woman in hospital at night for healthcare
    Image attribution tooltip
    Marco VDM via Getty Images
    Image attribution tooltip
    Sponsored by Pearson

    How rare-disease teams can fine-tune COAs to bridge meaningful change and measurable progress

    Discover why refining COAs is essential to capturing subtle, meaningful patient change—and how teams can close the sensitivity gap.

    Dec. 15, 2025
  • Recession arrow, Graph showing business decline on led screen
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Arcus cancels work on Gilead-partnered cancer combo after trial setback

    A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.

    By • Dec. 12, 2025
  • Brain pipette
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    AC Immune posts positive data for Parkinson’s immunotherapy

    Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug regulators for feedback to “potentially accelerate” the time to an approval filing. 

    By • Dec. 11, 2025
  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s three-pronged drug puts obesity field ‘on notice’

    Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar” for future obesity drug competitors, one analyst wrote.

    By Kristin Jensen • Dec. 11, 2025